marked.bio

Company

Sichuan Huiyu Pharmaceutical

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 2 trials shown

  1. Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors

    Not yet recruiting Phase 1/2 Sichuan Huiyu Pharmaceutical Started 2026Primary completion 2028-04 NCT07789327

    Test Product HY07121 for Injection (Subcutaneous)

    …phageal cancer, Microsatellite Instability-High / Mismatch Repair-Deficient Solid Tumors (MSI-H/dMMR) solid tumors, cervical cancer, non-muscle-invasive bladder cancer, head and neck sq…

    MSI-H / dMMRSafety, Tolerability, Efficacy

  2. Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

    Recruiting Phase 1/2 Sichuan Huiyu Pharmaceutical Started 2024Primary completion 2026-12 NCT06243354

    Test product: HYP-2090PTSA

    Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

    KRAS G12CKRAS G12DSafety, Tolerability, Efficacy